Oncology

Recent advances and updates in oncology and cancer drug development.

Trioxacarcins disrupt cancer cell replication by binding and chemically-modifying genetic material.

Mucus can form a shield around cancerous cells to protect from chemotherapy drugs.

Mesothelioma is resistant to available drugs, requiring the need for new treatments.

Low levels of a specific protein in colorectal cancer offers potential treatment target.

Gene activity in lung tumors offers the potential to respond to chemotherapy.

Evista is typically given to women after menopause to treat and prevent osteoporosis and reduce the risk of invasive breast cancer.

Kinase inhibitors sorafenib and sunitinib found no more effective than placebo preventing disease recurrence after kidney tumor removal surgery.

Learning what doesn't work in the treatment of cancer still offers valuable insight.

Nanoparticles selectively target tumor vessels or cancerous cells.

Stimulator of interferon gene agonists may offer hope in the treatment of in lymphoma, multiple myeloma, and certain forms of leukemia.

Genetic and molecular specialized testing may improve targeted therapy for skin cancer.

New generation of oncology drugs could improve treatment for patients with therapy-resistant cancer.

Recent advances and updates in oncology and cancer drug development.

The targeted multi-kinase inhibitor sorafenib is the standard of care for advanced HCC, but it has limited therapeutic benefit.

Subset of T cells can confer therapeutic immune responses.

Nanoparticles can change shape to gain entry into diseased tissue and reduce the toxic effects of chemotherapy.

Investigational drug MLN8237 aids ABT-199 in killing neuroblastoma tumors in advanced mouse models.

Twitter can increase awareness and patient recruitment for clinical trials of cancer drugs.

Prostate specific membrane antigens offers new targets for potential prostate cancer drugs.

Histologic improvement greater with experimental drug versus placebo in patients with moderate-to-severe ulcerative colitis.

Study estimates health insurers can save $9.1 million over 5 years per 100 CML patients.

Out-of-pocket costs can lead to the reduced use of preventive services and increased use of preventive medications.

New treatment approach offers less severe side effects from chemotherapy.

Study finds incidence of post-traumatic stress symptoms in breast cancer patients to be underestimated.

Cell-based therapy shows promise in high-grade glioma.

Gene overexpressed in AML may offer new target for halting the spread of cancer.

Hops in beer contain antibacterial and anti-fungal properties, which could halt the growth of diseases.